LRRK2 and Parkinson disease: Studies have shown that mutations of LRRK2 enhance the aggregation of α-synuclein within Lewy bodies, promoting neurodegenerative changes.529–531 Thus, degrading LRRK2 protein represents a promising approach for treating PD.